Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Earnings muted by currencies push big pharma into acquisitions

This article was originally published in Scrip

Executive Summary

With the recent distractions of the annual JP Morgan Healthcare conference, Shire's acquisition of NPS Pharmaceuticals (scripintelligence.com, 12 January 2015) and the many fundraisings vying for investors' attention, you could have been forgiven for not realising that the full-year 2014 earnings season is already well under way (scripintelligence.com, 23 January 2015). With events like those, something as prosaic and anodyne as profitability has probably taken a back seat in investors' minds. However, reporting season may be about to rudely remind them that earnings and M&A are linked to each other as well as to last and this years' hot button issues of tax inversions and currency translations, respectively.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027621

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel